SEC Form 4 · accession 0001179110-17-011492
Kala Pharmaceuticals, Inc. · KALA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Romulus K Brazzell
Officer — Chief Medical Officer
Period of report
Aug 11, 2017
Accepted (ET)
Aug 15, 2017 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479419
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 11, 2017 | M | 36,094 | $0.68 | A | 36,094 | D | |
| Common Stock | Aug 11, 2017 | M | 16,168 | $0.68 | A | 52,262 | D | |
| Common Stock | Aug 11, 2017 | M | 44,313 | $2.30 | A | 96,575 | D | |
| Common Stock | Aug 11, 2017 | M | 12,150 | $3.34 | A | 108,725 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.68 | Aug 11, 2017 | M | 36,094 | D | — | May 10, 2023 | Common Stock | 36,094 | 0 | D |
| Stock Option (right to buy)F2 | $0.68 | Aug 11, 2017 | M | 16,168 | D | — | May 10, 2023 | Common Stock | 16,168 | 1,880 | D |
| Stock Option (right to buy)F3 | $2.30 | Aug 11, 2017 | M | 44,313 | D | — | Oct 2, 2024 | Common Stock | 44,313 | 18,247 | D |
| Stock Option (right to buy)F4 | $3.34 | Aug 11, 2017 | M | 12,150 | D | — | Jun 17, 2026 | Common Stock | 12,150 | 149,985 | D |
Explanation of responses
- F1The option with respect to these shares is fully vested.
- F2This option was granted on May 10, 2013 and vests over four years, with 25% of shares underlying the option vesting 12 months after the date the Issuer submits an investigational new drug application for its loteprednol etabonate program and an additional 2.0833% vesting at the end of each successive one-month period thereafter.
- F3This option was granted on October 2, 2014 and vests over four years, with 25% of the shares underlying the option vested on September 25, 2015 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.
- F4This option was granted on June 17, 2016 and vests over four years, with 25% of the shares underlying the option vested on June 17, 2017 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.